A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naive Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms EASE
- Sponsors Sanofi
- 04 Jul 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
- 04 Jul 2017 Planned primary completion date changed from 31 Dec 2017 to 1 Dec 2017.
- 04 Jul 2017 Status changed from recruiting to active, no longer recruiting.